Actively Recruiting
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
Led by City of Hope Medical Center · Updated on 2026-01-28
10
Participants Needed
1
Research Sites
224 weeks
Total Duration
On this page
Sponsors
C
City of Hope Medical Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
"This phase I trial investigates the effect of radiation therapy on the immune system, specifically CD8 positive (+) T cells, in lymphoma patients receiving bridging radiation therapy before CAR T-cell infusion, and metastatic patients with solid tumor malignancies receiving SBRT. CD8+ T cells are mainly found in lymph tissue and play a significant role in anti-tumor immunity. These cells can infiltrate tumor cells and kill them. Radiation therapy may recruit CD8 T cells and this recruitment may help with tumor control. Diagnostic procedures, such as zirconium Zr 89-Df-crefmirlimab positron emission tomography (PET), may be a less invasive way to check and monitor for CD8+ T cells before and after radiation therapy."
CONDITIONS
Official Title
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided informed consent
- Willing and able to follow all study procedures
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2
- Metastatic solid tumor cancer suitable for SBRT as determined by radiation oncologist
- Lymphoma patients allowed as determined by the principal investigator
- No changes in systemic cancer treatment for at least 2 months before starting SBRT
- Able to comply with daily PET scans after SBRT
- Meets clinical safety lab values per institution standards or investigator's discretion
- Negative pregnancy test for women of childbearing potential
- Agreement by males and females of childbearing potential to use effective double barrier contraception or abstain from heterosexual activity during the study and for 30 days after last CD8 PET tracer dose
- Childbearing potential defined as not surgically sterilized or not free from menses for more than 1 year (women only)
You will not qualify if you...
- Splenic disorders or prior splenectomy that interferes with CD8 imaging
- Uncontrolled illness or active infection
- History of allergic reactions to similar compounds as CD8 PET tracer
- Serious nonmalignant diseases or conditions compromising study goals
- Pregnant or breastfeeding women
- Any condition that contraindicates participation due to safety concerns
- Inability to comply with study procedures as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
City of Hope Medical Center
Duarte, California, United States, 91010
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here